Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature

ConclusionsThis case emphasizes the uncommon adverse effect of the anaplastic lymphoma kinase-targeted therapy alectinib causing acute renal failure manifesting as acute tubular necrosis. Recognition of alectinib nephropathy requires a thorough drug history and knowledge of risk factors that lessen its margin of safety at therapeutic ingestions. Frequent monitoring of renal functions and early nephrology referral significantly reduce the mortality and morbidity of these patients.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research